Eli Lilly’s COVID-19 antibody-drug has been granted emergency use authorization by the Food and Drug Administration (FDA), widening access to a therapy that has shown improvement in treating patients with mild to moderate cases of the CCP virus. Data from a late-stage trial last month showed that Eli Lilly’s combination therapy of two antibodies, bamlanivimab and etesevimab, helped cut the risk of hospitalization and death in COVID-19, the disease caused by the CCP (Chinese Communist Party) virus, in patients by 70 percent. The therapy will be available immediately, the Indianapolis-based pharmaceutical company said. U.S. drug regulators previously granted emergency use authorization to a treatment from Eli Lilly that just used bamlanivimab. Former President Donald Trump received a similar treatment developed by Regeneron Pharmaceuticals after he tested positive for COVID-19 in October 2020. “Today’s action, which provides another treatment for COVID-19, reflects the FDA’s strong commitment to working with sponsors to expand potential treatment …